Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
GeneDx (WGS) has been named one of Fast Company's World's Most Innovative Companies of 2025, ranking No. 2 in the Biotech category. The company is recognized for revolutionizing whole genome sequencing (WGS) with turnaround times as fast as 48 hours.
The company is leading innovation in genomic newborn screening (gNBS) through their GUARDIAN study, the largest of its kind examining gNBS in diverse newborn populations. GeneDx's screening capabilities now cover over 450 actionable genetic conditions that traditional newborn screening methods typically miss.
With 25 years of experience, GeneDx focuses on delivering early genetic disease diagnosis and improving healthcare outcomes through genomic insights. Their approach aims to transform healthcare delivery by identifying conditions before symptoms appear, potentially reducing healthcare system burden and improving patient outcomes.
GeneDx (WGS) è stata nominata una delle Aziende più Innovative del Mondo nel 2025 da Fast Company, classificandosi al secondo posto nella categoria Biotech. L'azienda è riconosciuta per aver rivoluzionato il sequenziamento dell'intero genoma (WGS) con tempi di risposta rapidi, fino a 48 ore.
L'azienda guida l'innovazione nello screening genomico dei neonati (gNBS) attraverso il loro studio GUARDIAN, il più grande del suo genere che esamina il gNBS in popolazioni neonatali diverse. Le capacità di screening di GeneDx ora coprono oltre 450 condizioni genetiche azionabili che i metodi tradizionali di screening neonatale tendono a perdere.
Con 25 anni di esperienza, GeneDx si concentra sulla diagnosi precoce delle malattie genetiche e sul miglioramento dei risultati sanitari attraverso approfondimenti genomici. Il loro approccio mira a trasformare la fornitura di assistenza sanitaria identificando le condizioni prima che compaiano i sintomi, riducendo potenzialmente il carico sul sistema sanitario e migliorando i risultati per i pazienti.
GeneDx (WGS) ha sido nombrada una de las Empresas Más Innovadoras del Mundo de 2025 por Fast Company, ocupando el segundo lugar en la categoría Biotech. La empresa es reconocida por revolucionar el secuenciación del genoma completo (WGS) con tiempos de respuesta tan rápidos como 48 horas.
La empresa lidera la innovación en el cribado genómico neonatal (gNBS) a través de su estudio GUARDIAN, el más grande de su tipo que examina el gNBS en diversas poblaciones neonatales. Las capacidades de cribado de GeneDx ahora cubren más de 450 condiciones genéticas accionables que los métodos tradicionales de cribado neonatal suelen pasar por alto.
Con 25 años de experiencia, GeneDx se centra en ofrecer un diagnóstico temprano de enfermedades genéticas y mejorar los resultados de salud a través de conocimientos genómicos. Su enfoque busca transformar la prestación de atención médica al identificar condiciones antes de que aparezcan los síntomas, lo que podría reducir la carga del sistema de salud y mejorar los resultados para los pacientes.
GeneDx (WGS)는 Fast Company의 2025년 세계에서 가장 혁신적인 기업 중 하나로 선정되었으며, 생명공학(Biotech) 분야에서 2위를 차지했습니다. 이 회사는 전체 유전체 시퀀싱(WGS)을 혁신하여 48시간 이내의 빠른 결과를 제공하는 것으로 인정받고 있습니다.
회사는 다양한 신생아 집단에서 gNBS를 조사하는 가장 큰 규모의 GUARDIAN 연구를 통해 유전체 신생아 스크리닝(gNBS)의 혁신을 이끌고 있습니다. GeneDx의 스크리닝 능력은 이제 전통적인 신생아 스크리닝 방법이 놓치는 450개 이상의 실행 가능한 유전적 질환을 포괄합니다.
25년의 경험을 바탕으로 GeneDx는 조기 유전 질환 진단을 제공하고 유전적 통찰력을 통해 건강 관리 결과를 개선하는 데 집중하고 있습니다. 그들의 접근 방식은 증상이 나타나기 전에 상태를 식별하여 건강 관리 시스템의 부담을 줄이고 환자의 결과를 개선하는 것을 목표로 하고 있습니다.
GeneDx (WGS) a été désignée comme l'une des entreprises les plus innovantes au monde en 2025 par Fast Company, se classant au deuxième rang dans la catégorie Biotech. L'entreprise est reconnue pour avoir révolutionné le séquencement du génome entier (WGS) avec des délais de réponse aussi rapides que 48 heures.
L'entreprise est à la pointe de l'innovation dans le dépistage génomique des nouveau-nés (gNBS) grâce à son étude GUARDIAN, la plus grande de son genre examinant le gNBS dans des populations néonatales diverses. Les capacités de dépistage de GeneDx couvrent désormais plus de 450 conditions génétiques exploitables que les méthodes de dépistage néonatal traditionnelles ont tendance à manquer.
Avec 25 ans d'expérience, GeneDx se concentre sur la fourniture de diagnostics précoces des maladies génétiques et l'amélioration des résultats de santé grâce à des connaissances génomiques. Leur approche vise à transformer la prestation des soins de santé en identifiant les conditions avant l'apparition des symptômes, ce qui pourrait réduire la charge du système de santé et améliorer les résultats pour les patients.
GeneDx (WGS) wurde von Fast Company als eines der innovativsten Unternehmen der Welt 2025 ausgezeichnet und belegt den zweiten Platz in der Biotech-Kategorie. Das Unternehmen wird für die Revolutionierung der ganzen Genomsequenzierung (WGS) mit Rücklaufzeiten von bis zu 48 Stunden anerkannt.
Das Unternehmen führt Innovationen im genomischen Neugeborenenscreening (gNBS) durch seine GUARDIAN-Studie an, die größte ihrer Art, die gNBS in verschiedenen Neugeborenenpopulationen untersucht. Die Screening-Fähigkeiten von GeneDx decken jetzt über 450 umsetzbare genetische Bedingungen ab, die traditionelle Neugeborenenscreening-Methoden typischerweise übersehen.
Mit 25 Jahren Erfahrung konzentriert sich GeneDx darauf, frühzeitige genetische Krankheitsdiagnosen zu liefern und die Gesundheitsversorgung durch genomische Erkenntnisse zu verbessern. Ihr Ansatz zielt darauf ab, die Gesundheitsversorgung zu transformieren, indem Bedingungen identifiziert werden, bevor Symptome auftreten, was potenziell die Belastung des Gesundheitssystems verringern und die Ergebnisse für die Patienten verbessern könnte.
- Achieved No. 2 ranking in Fast Company's Biotech category
- Industry-leading 48-hour turnaround time for whole genome sequencing
- Capability to screen for 450+ actionable genetic conditions in newborns
- Leading large-scale GUARDIAN study in genomic newborn screening
- None.
GeneDx recognized for its innovative approach to accelerating genetic diagnosis and transforming the future of healthcare by ending the diagnostic odyssey
“Since its inception 25 years ago, GeneDx has been the pioneer in bringing to life the promise of the Human Genome Project, and it’s an honor to be recognized for our ability to innovate at scale. Ultimately, our mission is to improve healthcare with the earliest diagnosis of genetic disease, made possible by the interpretation at scale of an individual’s genome,” said Katherine Stueland, President and CEO of GeneDx. “At GeneDx, patients are at the core everything we do, from improving clinical outcomes to delivering better health economics. As we look to the future, our innovation will fuel a future of genome-informed healthcare for everyone, from birth and through all stages of life.”
As the driving force behind scaling precision medicine, GeneDx is revolutionizing whole genome sequencing (WGS) to deliver faster, more accurate diagnoses to patients. With industry-leading innovations, GeneDx has slashed WGS turnaround time to as little as 48 hours, ensuring that critical answers reach patients and their families with unprecedented speed.
GeneDx is also leading a transformative shift in newborn screening (NBS), redefining the standard of care through groundbreaking research from the GUARDIAN study —the largest of its kind to explore the power of genomic newborn screening (gNBS) in a diverse newborn population. While traditional NBS varies by state and relies on biomarker detection, it often fails to catch conditions that lack clear biomarkers, leaving too many children undiagnosed until symptoms appear. This outdated approach is fueling a pipeline of sick children into an already overburdened healthcare system—when a better solution exists. Today GeneDx has the capability to deploy gNBS at scale, screening newborns for over 450 actionable genetic conditions that are currently overlooked by standard tests. By identifying these conditions before symptoms arise, GeneDx is not only giving children a healthier start in life but also alleviating the financial and emotional burdens of delayed diagnoses. Every investment in GeneDx fuels transformation and innovation across genomic testing, bringing the promise of genomic insights to more patients, more efficiently, and at an unparalleled scale.
“Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future,” said Fast Company editor-in-chief Brendan Vaughan. “This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward.”
To determine honorees, Fast Company’s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world.
The full list of Fast Company’s Most Innovative Companies honorees can now be found at fastcompany.com.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318109271/en/
Investor Relations Contact:
Investors@GeneDx.com
Media Contact:
Press@GeneDx.com
Source: GeneDx
FAQ
What is GeneDx's (WGS) ranking in Fast Company's Most Innovative Companies 2025?
How fast can GeneDx (WGS) deliver whole genome sequencing results?
How many genetic conditions can GeneDx's (WGS) newborn screening detect?
What is the GUARDIAN study by GeneDx (WGS)?
